$RARE will be top watch for tomorrow, watching this close in pre market, a pullback to 80$ would be lovely at 886 trigger although id take it on break over Fridays high w a tight stop, below low(fridays), take profits are labeled with tags in blue. Objective, get long get stop to break even asap adn let this run 3-5 days, collect profit, lets see guys.
Pattern recognized: Regular flat Elliot Correction Wave.
Thesis: Bullish sentiment.
Conclusion: waiting for fractal on the 5 min
My strategy: MEWT (MODIFIED ELLIOT WAVE THEORY).
***This does not constitute financial advice.***
NASDAQ:RARE stock analysis at 1D time frame, EMA20 and MACD(8,21,5) crossed up .
RSI (14) and RSI (7) > 50 , Relative Volume (over 3 month) > 3.0 all that yield to strong "Buy".
The target price will be at least +18%,
This is not a recommendation to "buy" or "sell", everyone should do according to his / her sole discretion .
this is what i call a fakeout break, broke 140 and tricked investors into thinking a new rally was coming, but sold aff right back under previous highs, bearish in short term bullish long term. ideal entry 110 sl 105 pt 140! goodluck :)
Hey traders, ULTRAGENYX PHARMACEUTICAL is in an uptrend with high sell volume traded in the middle of the session and sellers rejecting the VWAP. Looking at the TIMEFRAME M1 we see a panic it is heading to its last low point to start again in a price increase. Great chance to break the VWAP to recover the losses of the last session and finish on the first high of...
There has been about a 225% gain since the market bottom to the 5 weeks sideways action on 07/10, which is great action on a stock. During the 5 weeks sideways action there was little volume, which showed that large institutional buyers are not selling and maybe just some mom and pop holders are selling. This makes a great buy at 91.87 assuming the day that it...
RARE: Ultragenyx Pharmaceutical Inc.
2020-05-15 08:00:10
Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
RARE: Ultragenyx Pharmaceutical Inc.
2020-05-13 16:01:10
Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
